Off-target at-scale Scale Down Model verification of a marketed biopharmaceutical by Emmler, Markus et al.
Engineering Conferences International
ECI Digital Archives
Cell Culture Engineering XVI Proceedings
5-6-2018
Off-target at-scale Scale Down Model verification
of a marketed biopharmaceutical
Markus Emmler
Roche Diagnostics GmbH, Germany, markus.emmler@roche.com
Stefanie Menrad
Roche Diagnostics GmbH, Germany
Yosuke Watanabe
Cell Culture Development Chugai Pharmaceuticals, Japan
Follow this and additional works at: http://dc.engconfintl.org/ccexvi
Part of the Engineering Commons
This Abstract and Presentation is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion
in Cell Culture Engineering XVI by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.
Recommended Citation
Markus Emmler, Stefanie Menrad, and Yosuke Watanabe, "Off-target at-scale Scale Down Model verification of a marketed
biopharmaceutical" in "Cell Culture Engineering XVI", A. Robinson, PhD, Tulane University R. Venkat, PhD, MedImmune E.
Schaefer, ScD, J&J Janssen Eds, ECI Symposium Series, (2018). http://dc.engconfintl.org/ccexvi/13
Process
Output
Scale Down Model Mean Prediction
(& Prediction Interval)
Actuals
Clinical Runs
10k Manufacturing 
CR1 /CR2
At Target Adapted for
Clinical Runs
High 
Mannose*2
1.00
(0.93-1.09)
2.07
(1.56 – 2.75)
1.73
2.07
Product Titer*2 1.00
(0.95-1.05)
1.22
(1.08 – 1.36)
1.03
1.11
IEC Pre*2; *3 1.00
(0.97-1.03)
1.11 
(1.01 – 1.21)
1.32 
1.20
IEC Main*2 1.00
(0.99-1.01)
0.99 
(0.95-1.04)
0.98
0.96
IEC Sub-1*2 1.00
(0.92-1.08)
1.11 
(0.90-1.31)
1.21
1.42
-1 0 1
High Mannose
Product titer
IEC Pre*3
IEC Main
IEC Sub-1
Off-target at-scale scale down model verification of a 
marketed biopharmaceutical
Markus Emmler & Stefanie Menrad, Cell Culture Development Roche Pharmaceuticals, Germany - markus.emmler@roche.com
Yosuke Watanabe, Cell Culture Development Chugai Pharmaceuticals, Japan
Background
Key Outcomes
• Challenge: Development of a process update for a marketed monoclonal antibody applying Quality by Design (QbD) principles
• Based on literature data*1, High Mannose (HM) content was identified as a new Critical Quality Attribute (CQA)
• In order to set appropriate HM specification ranges, a clinical pharmacokinetic (PK) study was accomplished
• The study was supplied with material of increased HM content from two 10,000 L scale runs with adapted process parameters
• Other quality attributes should be maintained as close to target as possible, process parameter changes should be minimal
• Predictions of a regression model based on Scale Down Model (SDM) data were used to decide which process parameters to
adapt to achieve this goal
• These two clinical runs (CR) provide the rare opportunity of a SDM verification off-target
*1 Goetze AM et al., „High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans“, Glycobiology 2011 Jul;21(7):949-59
• The desired quality attribute profile was achieved in two manufacturing runs with remarkable accuracy providing additional 
evidence of the SDM predictability
• Confidence is increased in the capability of the resultant control system which has been submitted to authorities for a post 
licensure manufacturing change
Table 1: Selected normalized data of SDM predictions
and actual results of clinical supply runs
Figure 1: Set of adapted and not 
adapted process parameters
(off-target) as used in clinical
supply runs Figure 2: Reported cell culture
SDM qualification results at target
(selected data)
*2 Data normalized to SDM mean prediction at target (=1.00)
*3 SDM offset in clinical runs (Table 1) as well as in SDM qualification at target (Figure 2)    
could be explained by a technical root cause
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